AHA Launches Trial to Improve Diagnosis of Underrecognized Heart Condition ATTR-CM
The American Heart Association (AHA) has launched a multicenter cluster randomized trial, known as TTRANSLATE-ATTR, to address the frequent underdiagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) in older adults with heart failure. Recent statistics indicate that up to 13% of older adults hospitalized with heart failure with preserved ejection fraction may have this condition. The study aims to evaluate whether a structured, provider-focused educational intervention can improve diagnostic testing and confirmed diagnoses compared to usual care. Participating hospitals within the AHA’s Get With The Guidelines - Heart Failure program are randomized to receive evidence-based tools, including expert coaching and diagnostic algorithms. Led by a steering committee including Dr. Gregg C. Fonarow, the trial leverages existing infrastructure to assess real-world clinical practice changes. Data analysis is conducted independently by the Duke Clinical Research Institute, while financial support is provided by AstraZeneca. If successful, the findings could inform broader dissemination strategies across more than 800 participating hospitals, potentially scaling responsible adoption of improved diagnostic protocols for ATTR-CM.
Wire timeline
AHA Launches Trial to Improve Diagnosis of Underrecognized Heart Condition ATTR-CM
The American Heart Association (AHA) has launched a multicenter cluster randomized trial, known as TTRANSLATE-ATTR, to address the frequent underdiagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) in older adults with heart failure. Recent statistics indicate that up to 13% of older adults hospitalized with heart failure with preserved ejection fraction may have this condition. The study aims to evaluate whether a structured, provider-focused educational intervention can improve diagnostic testing and confirmed diagnoses compared to usual care. Participating hospitals within the AHA’s Get With The Guidelines - Heart Failure program are randomized to receive evidence-based tools, including expert coaching and diagnostic algorithms. Led by a steering committee including Dr. Gregg C. Fonarow, the trial leverages existing infrastructure to assess real-world clinical practice changes. Data analysis is conducted independently by the Duke Clinical Research Institute, while financial support is provided by AstraZeneca. If successful, the findings could inform broader dissemination strategies across more than 800 participating hospitals, potentially scaling responsible adoption of improved diagnostic protocols for ATTR-CM.
American Heart Association